CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study
Seong Hoon Shin, Ho Sup Lee, Yang Soo Kim, Young Jin Choi, Sung Hyun Kim, Hyuk Chan Kwon, Sung Yong Oh, Jung Hun Kang, Chang Hak Sohn, Sang Min Lee, Jin Ho Baek, Young Joo Min, Choongrak Kim, Joo Seop Chung
Cancer Research and Treatment. 2014;46(4):331-338.   Published online 2014 July 21    DOI: https://doi.org/10.4143/crt.2013.130

Excel Download

Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study
Cancer Research and Treatment. 2014;46(4):331-338   Crossref logo
Link1 Link2

An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain
BMC Palliative Care. 2009;8(1):   Crossref logo
Link1 Link2 Link3 Link4

Poster 269: Open-label Extension Study on the Long-Term Safety, Impact on Quality of Life and Clinical Utility of OROS® Hydromorphone Extended Release in Patients with Chronic Low Back Pain
PM&R. 2009;1:S220-S221   Crossref logo
Link1 Link2 Link3 Link4

Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain
Clinical Therapeutics. 2006;28(1):86-98   Crossref logo
Link1 Link2

1161 Tasimelteon Shows Persistence Of Efficacy In Improving Sleep Disturbances In Patients With Smith-Magenis Syndrome (SMS) In Open-Label Extension Study
Sleep. 2020;43(Supplement_1):A442-A444   Crossref logo
Link1 Link2

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
Clinical Ophthalmology. 2012;739   Crossref logo
Link1

Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study
Journal of Korean Medical Science. 2016;31(12):1914   Crossref logo
Link1 Link2 Link3

Open-label extension study on the long-term efficacy, safety, and impact on quality of life of OROS® hydromorphone extended release in patients with chronic low back pain
The Journal of Pain. 2009;10(4):S49   Crossref logo
Link1 Link2

Open-Label Study on the Long-Term Efficacy, Safety, and Impact on Quality of Life of OROS Hydromorphone ER in Patients with Chronic Low Back Pain
Pain Medicine. 2010;11(10):1477-1488   Crossref logo
Link1

Efficacy and tolerability of once-daily OROS® hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: Results of a 6-week, randomized, open-label, noninferiority analysis
Clinical Therapeutics. 2007;29(5):874-888   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.